The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion

Inclusion Criteria: 1. Men or women ≥ 18 years old; 2. Acute occlusion of M1 or intracranial internal carotid artery within 72 hours; 3. For patients who receive recombinant tissue-type plasminogenactivator therapy, the arterial occlusive lesion scale of 24-72 hours post-thrombolysis imaging should be 0 or 1; 4. Ischemic stroke with National Institutes of Health Stroke Scale ≥ 4; 5. Baseline mRS before this stroke onset less than 2; 6. Able and willing to comply with study requirements; 7. Signed informed consent by patients self or legally authorized representatives. Exclusion Criteria: 1. Cerebral hemorrhage; 2. Posterior circulation infarction; 3. Severe tendency of hemorrhage, such as thrombocytopenia, leukemia, allergic purpura; 4. Currently using urinary kallidinogenase or alprostadil; 5. Be allergic to NBP or celery; 6. Impaired liver function (alanine aminotransferase or glutamic oxalacetic transaminase ≥ 3×upper limit of normal) or renal function (serum creatinie ≥ 1.5mg/dl); 7. Patients with evidence of severe congestive heart failure or history of end-stage cardiovascular disease (e.g. congestive heart failure New York Heart Association Class III or IV); 8. Metastatic neoplasm or multiple organ failure; 9. Pregnancy or breastfeeding; 10. History of mental instability or dementia.